Alkermes (ALKS) Other Accumulated Expenses (2011 - 2026)
Alkermes' (ALKS) quarterly Other Accumulated Expenses came in at $136.8 million in Q1 2026, up 64.63% year-on-year from $83.1 million in Q1 2025, and up 37.94% on a QoQ basis from $99.2 million in Q4 2025.
Alkermes (ALKS) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Other Accumulated Expenses data on file, last reported at $136.8 million in Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 64.63% year-over-year to $136.8 million in Q1 2026; TTM through Mar 2026 was $136.8 million, a 64.63% increase from a year earlier, with the FY2025 full-year figure at $99.2 million, up 44.26% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $136.8 million, up from $99.2 million in the prior quarter.
- Over the last five years, Other Accumulated Expenses for ALKS reached as high as $136.8 million in Q1 2026 and fell as low as $67.3 million in Q3 2024.
- Historically, Other Accumulated Expenses has averaged $93.3 million across 5 years, with a median of $91.0 million in 2022.
- Across the five-year window, Other Accumulated Expenses decreased 25.12% in 2024 and jumped 64.63% in 2026, its largest moves.
- Year by year, Other Accumulated Expenses stood at $108.2 million in 2022, then decreased by 15.12% to $91.8 million in 2023, then dropped by 25.12% to $68.7 million in 2024, then surged by 44.26% to $99.2 million in 2025, then jumped by 37.94% to $136.8 million in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $136.8 million in Q1 2026, $99.2 million in Q4 2025, and $79.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.79 Mn |
| Dec 31, 2025 | 99.17 Mn |
| Sep 30, 2025 | 79.79 Mn |
| Jun 30, 2025 | 90.00 Mn |
| Mar 31, 2025 | 83.09 Mn |
| Dec 31, 2024 | 68.74 Mn |
| Sep 30, 2024 | 67.26 Mn |
| Jun 30, 2024 | 85.64 Mn |
| Mar 31, 2024 | 81.59 Mn |
| Dec 31, 2023 | 91.81 Mn |
| Sep 30, 2023 | 88.45 Mn |
| Jun 30, 2023 | 98.35 Mn |
| Mar 31, 2023 | 105.30 Mn |
| Dec 31, 2022 | 108.16 Mn |
| Sep 30, 2022 | 117.06 Mn |
| Jun 30, 2022 | 93.90 Mn |
| Mar 31, 2022 | 91.02 Mn |
| Dec 31, 2021 | 75.51 Mn |
| Sep 30, 2021 | 101.44 Mn |
| Jun 30, 2021 | 68.05 Mn |